If you or a loved one have been diagnosed with early stage Alzheimer’s disease, you may be eligible to participate in the PICASSO Alzheimer’s Study.
The last true breakthrough in Alzheimer’s disease treatment happened with the development of the drug donepezil (Aricept®) to treat Alzheimer’s disease (AD) in 1995. Now there is a need for new drugs to be developed that not only help reduce the cognitive impairment of AD and other dementias, but that also could help restore cognitive function and heal the damage AD causes to the brain.
The purpose of the PICASSO research study is to evaluate an investigational drug called BPN14770 as a possible treatment for patients with early stage AD.
To be eligible for this study, you must:
- Be 55 to 85 years of age
- Have been diagnosed with early stage AD or Mild Cognitive Impairment, which our physicians may determine is actually early stage AD
- Have been taking Aricept® (donepezil), or another cholinesterase inhibitor, for treatment of AD for at least 2 months
- Be supported by a caregiver who is willing and able to ensure the patient takes their study medications, attends clinic visits, and follows study procedures as instructed
Qualified participants will be seen by a doctor and receive all study-related exams, care and medications at no cost. Compensation for time and travel may be available.